AliveCor brings pocket-sized Kardia 12L ECG system with AI diagnostics to Europe

AliveCor received European CE Mark certification for Kardia 12L and on April 15, 2026 began rolling out the system to the markets of France, Germany, Italy, Spain and the United Kingdom. This is a pocket 12-lead ECG for healthcare workers: instead of the usual cart with multiple wires, the device uses five electrodes, one cable and built-in AI for rapid analysis of cardiac data.

What AliveCor is launching

This is not a consumer gadget, but a clinical tool for doctors, nurses and other personnel who need to quickly take an ECG outside a fully equipped office. After obtaining CE Mark, the company can sell the system in the European Economic Area, with initial deliveries going directly to five major markets. AliveCor positions Kardia 12L as the first portable 12-lead ECG system with AI and single-cable design, designed to work right at the point of care.

For Europe at launch, the KAI 12L version is available, capable of providing 35 cardiological conclusions: 14 for rhythm and 21 for signal morphology. This list includes not only common arrhythmias, but also more critical scenarios like acute myocardial infarction and common types of ischemia. This is important because standard ECG remains the basic way to quickly spot dangerous changes, and access to it outside the hospital is often limited by the size and complexity of classical systems.

How Kardia 12L differs

A standard 12-lead ECG machine is a cart or stationary system with ten electrodes, wires and significant setup time. Kardia 12L aims to eliminate this operational burden. The device weighs about 130 grams, runs on battery and fits in a coat pocket. For recording you need five electrodes and one cable: the system captures eight diagnostic leads and synthesizes four more. Because of this, it can be used where bulky equipment is inconvenient: in primary care, emergency departments, pharmacies, rural clinics and on home visits.

• Weight around 130 grams and battery-powered
• Five electrodes and one cable instead of the classical bulky setup
• 35 conclusions in the European version, including arrhythmias, infarction and ischemia
• Nearly 30% faster ECG acquisition compared to the standard setup
• Record sharing with colleagues through the KardiaPro web platform

The simplified design benefits not only the clinic but also the patient. According to the company and published research, ECG acquisition time is reduced by nearly 30% compared to the standard setup. Patients don't need to fully undress, and staff requires minimal training. For hospitals, this means a faster examination flow, and for small care facilities, a chance to actually get access to 12-lead ECG without separate bulky infrastructure.

What the launch has shown

Kardia 12L already has a history of use in America. After FDA approval and commercial launch in the US on June 25, 2024, the system was deployed in more than 250 clinical practices and used on tens of thousands of patients. On AliveCor's product page, there are currently figures of over 27,000 examined patients and more than 4,000 cases of myocardial infarction and ischemia that the system helped identify.

Outside the US, the platform has also launched in India, Australia, New Zealand, Vietnam and Canada. There is also an important regulatory detail. On January 13, 2026, the FDA approved the expanded KAI 12L version with 39 cardiological conclusions, but the European release is launching with 35.

This gap is due not to hardware but to the fact that the feature set depends on geography and individual approvals. According to AliveCor, the KAI 12L algorithms were trained and validated on more than 1.75 million ECGs from leading American medical centers.

For the medtech market, this is a strong argument: the company is selling not just a compact device, but an accumulated clinical database around it.

What this means

AliveCor is not trying to replace a cardiologist with a smartphone for the mass user. It's pushing a different idea: to make full 12-lead ECG mobile and available where it simply wasn't at hand before. If the European launch goes well, the market will get another example of how narrowly specialized medical AI is embedded not in beautiful demos, but in the actual workflow of doctors — with clear benefits in time, accessibility and speed of patient routing.